Articles tagged with Blood Coagulation
Researchers at University of Leeds discover how platelet myosin is normally kept inactive, but genetic mutations push it out of balance leading to disease. This breakthrough sheds light on the role of platelet myosin in blood clotting and shedding new hope for treating bleeding disorders.
Researchers at McGill University have developed a rapid way to engineer blood clots that stop severe bleeding and support tissue healing more effectively. The technique, called 'click clotting,' links red blood cell surface proteins through a chemical reaction, resulting in a biocompatible clot.
A team of researchers at North Carolina State University has created an injectable microgel called B-knob triggered microgels (BK-TriGs) that can help reduce bleeding in infants during surgery. The microgel works by mimicking the mechanical properties of natural platelets, which helps to create fibrin networks and stanch bleeding.
A nationwide Japanese trial found that catheter ablation did not reduce the risk of recurrent stroke or major cardiovascular events in patients with atrial fibrillation who had recently experienced a stroke. The study, which enrolled 251 patients and followed them for over three years, suggests that routine addition of catheter ablatio...
A study by Professor Bryan Fry and Sam Campbell from the University of Queensland found that scorpion venom activates major clotting factors in human blood, particularly Factors VII and X. The research also identified small-molecule metalloprotease inhibitors that can neutralize the procoagulant effect.
Researchers developed a highly sensitive blood test that can detect initial thrombin generation, a key trigger in blood clot formation. The test distinguishes between pathway-specific clotting abnormalities and suggests personalized treatment strategies, potentially predicting clinical outcomes.
Researchers tracked 120 older veterans taking gabapentinoids and loop diuretics, finding that only 4 doctors correctly identified the gabapentinoids as the cause of leg swelling. The study highlights the dangers of 'prescribing cascades' and emphasizes the need for regular monitoring and alternative treatment options.
Akassoglou's research discovered that blood protein fibrin causes toxic immune reactions in the brain, leading to neurodegeneration and disease progression. Her new immunotherapy aims to neutralize these effects, protecting against Alzheimer's and other neurological conditions.
Researchers at Salk Institute and UC San Diego have identified a unique sugar called HSAT as a potential therapeutic target for slowing tumor progression and metastasis in pancreatic ductal adenocarcinoma. Boosting HSAT levels may slow the formation and spread of pancreatic cancer, leading to improved survival rates among patients.
A University of Queensland study suggests the antivenom given to people bitten by Eastern Brown Snakes may not be as effective as it could be due to geographic variations in venom. The research found that venom from southern Australia has a strong, stable blood clot, while northern populations trigger fragile but rapid clots.
A novel 3D culture method enables self-organization of precursor cell types into functional liver organoids capable of producing essential clotting factors. The breakthrough advances organoid-based therapies, drug testing, and disease modeling for liver diseases, including hemophilia A.
The new guidelines aim to improve health outcomes by providing evidence-based recommendations for managing VTE in children. Direct oral anticoagulants are now recommended as a first-line treatment option in many cases.
A new framework for assessing traumatic brain injuries (TBI) will provide more accurate diagnoses and treatments, leading to better patient outcomes. The framework incorporates clinical symptoms, biomarkers, imaging scans, and modifiers to determine the severity of injury and predict recovery.
Researchers are developing a cutting-edge blood test that can accurately track clot formation and breakdown. This innovative approach has the potential to improve patient treatment and reduce complications associated with current treatments.
Researchers discovered a promising new approach to treating hemorrhagic shock, which tripled survival rates and maintained healthy organ function. Activating Protein Kinase C epsilon (PKC-ε) significantly improved early survival rates and physiological stability following severe hemorrhage.
A new analysis found that oral hormone therapy can lower levels of lipoprotein(a), a genetic risk factor associated with higher risk of heart attack and stroke. Hormone therapy also improved biomarkers of cardiovascular health, including cholesterol levels.
A new study found that white blood cells that remember past inflammation events are quick to overreact, raising the risk of blood clots. Researchers discovered that these immune cells, called myeloid cells, have increased blood-clotting activity long after the initial inflammatory event.
A novel LASSO-derived model was developed to predict coagulation disorders after coronary artery bypass grafting (CABG) in elderly individuals. The model demonstrated good prediction performance, identifying preoperative and intraoperative variables associated with coagulation disorders.
A study published in Research and Practice in Thrombosis and Haemostasis found that adding amniotic fluid to plasma improves blood's ability to thicken and clot. The research also identified changes in amniotic fluid composition over time, which can affect maternal and fetal health.
A recent study has discovered that saliva contains special vesicles with extrinsic tenase complexes, which trigger rapid coagulation of the blood in haemophilic patients. This finding provides significant contributions to understanding the disease and its treatment options.
A recent study by Michigan Medicine found that reducing the dose of popular blood thinners like Xarelto and Eliquis can lower the risk of future bleeding events. The research team analyzed nearly 1,000 cases of patients who took these medications to prevent recurrent clots after having a blood clot.
A clinical trial demonstrated the efficacy and tolerability of concizumab, a new drug for haemophilia patients, reducing bleeding rates. Concizumab works by blocking an anticoagulant factor, restoring the delicate balance between clotting and anti-clotting factors.
Researchers at the University of British Columbia have developed a groundbreaking coating that mimics natural blood vessels to reduce clotting and bleeding risks. The coating's unique properties prevent clot formation without disrupting normal blood functions, offering a promising alternative to high-risk blood thinners.
Researchers discovered that the blood coagulation protein fibrin causes unusual clotting and inflammation in COVID-19, suppressing the body's ability to clear the virus. A promising therapeutic strategy has been identified, targeting fibrin to combat these deleterious effects.
A new anticoagulant with on-demand reversible activity has been developed by a team from UNIGE and the University of Sydney. This breakthrough offers a more reliable and easier-to-use option for surgical procedures, reducing the risk of serious bleeding associated with current treatments.
Synthetic platelets made of hydrogel nanoparticles mimic the size and shape of human platelets, promoting clotting and healing. The innovative device has shown promising results in animal models and is being developed for clinical use to treat various medical conditions.
Researchers at Rensselaer Polytechnic Institute have developed a patented process to produce heparin in the lab, offering a consistent and safe supply of the essential medicine. The discovery has the potential to revolutionize the production of heparin, reducing reliance on animal-derived sources and addressing global supply chain issues.
New research reveals that the age at which individuals are tested for VWD significantly affects their diagnosis, with older patients more likely to be misdiagnosed. The study also found that as people with VWD get older, they respond better to treatment, potentially reducing medication and side effects.
Octapharma's Balfaxar, a prothrombin complex concentrate, has received FDA approval for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy. The product demonstrated effective hemostasis in 94.6% of patients and was non-inferior to comparator Kcentra.
Researchers at UBC and the University of Michigan have discovered a new compound, MPI 8, that prevents blood clots without increasing bleeding risk. This breakthrough could lead to improved treatment options for patients affected by blood clots.
A new study has deciphered a central regulatory mechanism of fibrin formation, proposing therapeutic approaches. Glycoprotein V controls thrombin activity and limits fibrin formation.
Wilate prophylaxis showed an 84% reduction in bleeding episodes and improved quality of life in children and adults with all types of VWD. The treatment reduced the frequency of bleeding episodes by lowering the mean total annualized bleeding rate compared to on-demand treatment.
A new injectable hydrogel has been developed with enhanced shear-thinning properties, improved cellular biocompatibility, and significantly reduced clotting times. The biomaterial was created by adding sodium phytate to a gelatin-based compound, promoting even greater cohesion and triggering the initiation of blood coagulation.
Researchers from McGill University developed a medical adhesive inspired by flatworms that uses suction to absorb blood and promote blood coagulation. The adhesive can be removed without causing re-bleeding, making it a potential replacement for wound sutures or delivering drugs.
Patients with a history of unprovoked venous thromboembolism who stop treatment after negative D-dimer tests experience an eight-fold increased risk of recurrence compared to those on low-dose apixaban. Low-dose apixaban was found safe and effective for these patients
Scientists found a connection between the SARS-CoV-2 virus and the production of misfolded proteins called amyloids, which can cause complex symptoms and damage in organs such as the heart and kidneys. The researchers' discovery may help explain why COVID-19 often affects multiple parts of the body.
The UCF-developed real-time blood monitor uses an optical fiber to assess blood status and can be inserted directly into heart-lung machines or catheters without withdrawing blood from patients. This device has been shown to save doctors critical time during life-or-death operations, particularly in surgeries on infants.
A post-hoc subgroup analysis of the AFIRE trial found that reduced kidney function significantly influences bleeding events during antithrombotic therapy. Patients with healthy kidney function have a decreased risk of bleeding over time, while those with reduced kidney function remain at high risk.
A study examining autopsy tissue samples from COVID-19 patients found frequent and extensive blood clots within heart vessels, but no typical endothelial cell changes. Instead, hypercoagulability of the blood caused by activated neutrophils was detected as a likely culprit.
A study published in Cardiovascular Research found that an anticoagulant medication can improve the survival of COVID-19 patients and shorten the duration of active SARS-CoV-2 infection. The medication, low-molecular-weight heparin, also curtails viral persistence by inhibiting the virus's ability to bind to cells.
Researchers at Nagoya City University develop a 10-amino acid sequence that enhances the cellular secretion of recombinant erythropoietin. The 'passport' sequence is recognized by a cargo receptor, allowing for improved production yields of biopharmaceuticals.
Researchers identified a cluster of immunoresolvents in blood that activate immune cells, enhancing the immune system's ability to fight bacterial infections. This new profiling procedure has potential applications in distinguishing between cancerous and healthy tissue.
A new device replicates the crucial interface between endothelial cells and circulating blood, enabling the diagnosis of blood clotting disorders and monitoring of anti-platelet therapy. The device uses chemically fixed human endothelial cells to mimic cellular and vascular flow conditions, increasing robustness and diagnostic accuracy.
The Mainz University Medical Center has been awarded a highly endowed Alexander von Humboldt Professorship worth €5 million to appoint renowned blood coagulation researcher Professor Dr. Wolfram Ruf. His research will significantly enhance the Rhineland-Palatinate science environment and its international competitiveness.
A study by LMU researchers found that neutrophils play a crucial role in blood coagulation and antimicrobial defense, trapping pathogens in small blood vessels. Excessive clotting, however, can lead to life-threatening conditions like heart attack and stroke.
Researchers have discovered that nonalcoholic beer can impart cardiovascular benefits without the negative effects of alcohol. The study found that nonalcoholic beer reduced platelet activation and blood coagulation just as well as alcoholic beverages, which may help prevent conditions such as coronary heart disease and atherosclerosis.
Researchers discover that a platelet molecule called phosphatidylserine plays a key role in activating the final step of blood coagulation. The finding could lead to new treatments for clotting disorders, such as heart attacks and strokes.